This site is intended only for Australian Healthcare Professionals




Sign In or RegisterLog Out Our medicinesTherapy areasExplore contentExplore contentEventsVideosMaterialsLet’s connectLet's ConnectContact usAsk a questionPfizer Medical InformationStay connectedSuggest a topicPharmacy HubKnowledge Hub



AboutStudy Design1L study design2L+ study designEfficacy1L overall efficacy1L CNS efficacy1L 36-month overall efficacy1L 36-month CNS efficacy2L+ efficacySafetyPooled Safety: all lines1L safety2L+ safetyDosing & Therapy ManagementDosingTherapy managementResourcesEventsMaterialsVideos
Prescribing InformationPatient InformationIndicationPatient Site
A once-daily oral treatment with flexible dosing to manage adverse reactions1

For special warnings and precautions for use, please see the LORVIQUA Product Information.

  • LORVIQUA should be swallowed whole, with or without food—never chewed, crushed, or split1
  • LORVIQUA is contraindicated in patients taking strong CYP3A inducers concomitantly* and in those with hypersensitivity to LORVIQUA or any of the excipients in LORVIQUA tablets1
  • For patients taking LORVIQUA, alternative concomitant medicinal products with less potential to inhibit CYP3A should be considered1,*
  • Patients should avoid grapefruit products while taking LORVIQUA1
  • There are specific recommendations for dose modifications related to particular ARs1
*Please refer to the LORVIQUA Product Information for recommendations regarding the use of CYP3A inducers and CYP3A inhibitors.AR=adverse reaction; CYP3A=cytochrome P450 3A.ReferencesReference:LORVIQUA Product Information.
Dosing & Therapy Management
LORVIQUA safety profile
Review the safety Loading
LORVIQUA efficacy
Discover the data Loading

Before prescribing, please review Product Information available here.

This medicinal product is subject to additional monitoring in Australia. This will allow quick identification of new safety information.​
Healthcare professionals are asked to report any suspected adverse events at

PBS Information: Authority required. Locally advanced or metastatic ALK+ non-small cell lung cancer.​
Refer to PBS Schedule for full authority information.​

LORVIQUA® is a registered trademark of Pfizer.

PP-LOR-AUS-0073 September 2023
PfizerPro AccountPfizerPro Account

To access further materials, resources and receive communication about Pfizer medicines and vaccines.

Sign inRegisterAccountSign Out

The site is intended for Australian healthcare professionals.


©2023 Pfizer Australia Pty Ltd. Sydney, Australia. All rights reserved.


PP-UNP-AUS-0551 12/23.

You are now leaving Pfizer
You are leaving PfizerPro.
You may be directed to a third-party website.
Please note third-party websites are not controlled by Pfizer or subject to our privacy policy.
PP-UNP-AUS-0551 12/23.